The future of heart failure diagnosis, therapy, and management

Circulation

Volumn 133, Issue 25, 2016, Pages 2671-2686

  Udelson, James E ^a   Stevenson, Lynne Warner ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

other

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL; ENKEPHALINASE INHIBITOR; INOTROPIC AGENT; ISOSORBIDE MONONITRATE; METOPROLOL SUCCINATE; MINERALOCORTICOID ANTAGONIST; PREALBUMIN; SACUBITRIL; SILDENAFIL; VALSARTAN;

ANOREXIA; ARTICLE; ASSISTED CIRCULATION; BATISTA OPERATION; BETA ADRENERGIC RECEPTOR BLOCKING; CACHEXIA; CARDIAC IMAGING; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOPULMONARY EXERCISE TEST; CARDIORENAL SYNDROME; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; COMORBIDITY; CONGENITAL HEART DISEASE; DIASTOLIC DYSFUNCTION; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXCITATION CONTRACTION COUPLING; EXTRACELLULAR SPACE; EXTRACORPOREAL OXYGENATION; GENETIC ENVIRONMENT INTERACTION; GENETIC TRANSFECTION; GENOME; GENOTYPE ENVIRONMENT INTERACTION; GRAFT RECIPIENT; HEALTH CARE QUALITY; HEART AFTERLOAD; HEART AMYLOIDOSIS; HEART ASSIST DEVICE; HEART ATRIUM ENLARGEMENT; HEART CYCLE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE FAILURE; HEART SURGERY; HEART TRANSPLANTATION; HEART VALVE REGURGITATION; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INDIVIDUALIZATION; KIDNEY FAILURE; LEFT VENTRICULAR ASSIST DEVICE; LIVER CONGESTION; LIVER DYSFUNCTION; MALIGNANT NEOPLASTIC DISEASE; MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT PREFERENCE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QRS INTERVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RIGHT VENTRICULAR ASSIST DEVICE; SARCOIDOSIS; STEM CELL TRANSPLANTATION; STUDY DESIGN; SUDDEN CARDIAC DEATH; THERAPEUTIC INDEX; TOTAL ARTIFICIAL HEART; TOTAL QUALITY MANAGEMENT; VENOUS CONGESTION; VENTRICULAR ASSIST DEVICE; WALL STRESS; ANIMAL; CARDIOLOGY; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM EXAMINATION; DISEASE MODEL; FORECASTING; HEART STROKE VOLUME; MASS COMMUNICATION; MEDICAL RESEARCH; MORTALITY; MULTIMODALITY CANCER THERAPY; PREDICTIVE VALUE; RISK FACTOR; TREATMENT OUTCOME; TRENDS;

ANIMALS; BIOMEDICAL RESEARCH; CARDIOLOGY; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; DIFFUSION OF INNOVATION; DISEASE MODELS, ANIMAL; FORECASTING; HUMANS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84975862644     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.023518     Document Type: Article

References (121)

1. Centers for Disease Control and Prevention, National Center for Health Statistics. 2010 National Ambulatory Medical Care Survey and 2010 National Hospital Ambulatory Medical Care Survey. For methodology, see National Center for Health Statistics, Public Use Data File Documentation: 2010 National Ambulatory Medical Care Survey and Public Use Data File Documentation: 2010 National Hospital Ambulatory Medical Care Survey. http://www.cdc.gov/nchs/ahcd/ahcd-questionnaires.htm. Accessed January 9, 2016
2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015 131 e29 322. doi: 10.1161/CIR.0000000000000152
3. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Piña IL, Trogdon JG, American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013 6 606 619. doi: 10.1161/HHF.0b013e318291329a
4. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS, Long-Term trends in the incidence of and survival with heart failure. N Engl J Med 2002 347 1397 1402. doi: 10.1056/NEJMoa020265
5. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM, Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006 355 251 259. doi: 10.1056/NEJMoa052256
6. Cubbon RM, Gale CP, Kearney LC, Schechter CB, Brooksby WP, Nolan J, Fox KA, Rajwani A, Baig W, Groves D, Barlow P, Fisher AC, Batin PD, Kahn MB, Zaman AG, Shah AM, Byrne JA, Lindsay SJ, Sapsford RJ, Wheatcroft SB, Witte KK, Kearney MT, Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras. Circ Heart Fail 2011 4 396 403. doi: 10.1161/CIRCHEARTFAILURE.110.959882
7. MacIntyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Finlayson A, Redpath A, Pell JP, McMurray JJ, Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000 102 1126 1131
8. Shafazand M, Schaufelberger M, Lappas G, Swedberg K, Rosengren A, Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry. Eur Heart J 2009 30 671 678
9. Stevenson LW, Pande R, Witness to progress. Circ Heart Fail 2011 4 390 392. doi: 10.1161/CIRCHEARTFAILURE.111.963066
10. Loh JC, Creaser J, Rourke DA, Livingston N, Harrison TK, Vandenbogaart E, Moriguchi J, Hamilton MA, Tseng CH, Fonarow GC, Horwich TB, Temporal trends in treatment and outcomes for advanced heart failure with reduced ejection fraction from 1993-2010: findings from a university referral center. Circ Heart Fail 2013 6 411 419. doi: 10.1161/CIRCHEARTFAILURE.112.000178
11. Stevenson LW, Lakdawala N, Zipes D, Jalife J, Ventricular arrhythmias in heart failure. In: Cardiac Electrophysiology: From Bench to Bedside Philadelphia, PA: Elsevier
12. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, American College of Cardiology Foundation; American Heart Association 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009 53 e1 e90. doi: 10.1016/j.jacc.2008.11.013
13. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013 128 1810 1852. doi: 10.1161/CIR.0b013e31829e8807
14. Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Inge PJ, Mehra MR, O'Connor CM, Reynolds D, Walsh MN, Yancy CW, Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 2010 122 585 596. doi: 10.1161/CIRCULATIONAHA.109.934471
15. Gold MR, Thébault C, Linde C, Abraham WT, Gerritse B, Ghio S, St John Sutton M, Daubert JC, Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation 2012 126 822 829. doi: 10.1161/CIRCULATIONAHA.112.097709
16. Birnie DH, Ha A, Higginson L, Sidhu K, Green M, Philippon F, Thibault B, Wells G, Tang A, Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail 2013 6 1190 1198. doi: 10.1161/CIRCHEARTFAILURE.113.000380
17. Sipahi I, Chou JC, Hyden M, Rowland DY, Simon DI, Fang JC, Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-Analysis of randomized controlled trials. Am Heart J 2012 163 260 7.e3. doi: 10.1016/j.ahj.2011.11.014
18. Bilchick KC, Kamath S, DiMarco JP, Stukenborg GJ, Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation 2010 122 2022 2030. doi: 10.1161/CIRCULATIONAHA.110.956011
19. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014 371 993 1004. doi: 10.1056/NEJMoa1409077
20. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC, PARADIGM-HF Investigators and Coordinators Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015 131 54 61. doi: 10.1161/CIRCULATIONAHA.114.013748
21. Katz AM, The "modern" view of heart failure: how did we get here? Circ Heart Fail 2008 1 63 71. doi: 10.1161/CIRCHEARTFAILURE.108.772756
22. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T, Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004 109 1594 1602. doi: 10.1161/01.CIR.0000124490.27666.B2
23. Hashim T, Sanam K, Revilla-Martinez M, Morgan CJ, Tallaj JA, Pamboukian SV, Loyaga-Rendon RY, George JF, Acharya D, Clinical characteristics and outcomes of intravenous inotropic therapy in advanced heart failure. Circ Heart Fail 2015 8 880 886. doi: 10.1161/CIRCHEARTFAILURE.114.001778
24. Pinney SP, Stevenson LW, Chronic inotropic therapy in the current era: old wines with new pairings. Circ Heart Fail 2015 8 843 846. doi: 10.1161/CIRCHEARTFAILURE.115.002481
25. Allen LA, Fonarow GC, Grau-Sepulveda MV, Hernandez AF, Peterson PN, Partovian C, Li SX, Heidenrich PA, Bhatt DL, Peterson ED, Krumholz HM, American Heart Association's Get With The Guidelines Heart Failure I Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: Insights from get with the guidelines. Circ Heart Failure 2014 7 251 260
26. Sung MM, Das SK, Levasseur J, Byrne NJ, Fung D, Kim TT, Resveratrol treatment of mice with pressure-overload-induced heart failure improves diastolic function and cardiac energy metabolism. Circ Heart Fail 2015 8 128 137
27. Middlekauff HR, Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure. Circ Heart Fail 2010 3 537 546. doi: 10.1161/CIRCHEARTFAILURE.109.903773
28. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourley LA, Jolly MK, Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993 329 1 7. doi: 10.1056/NEJM199307013290101
29. Grinstead WC, Francis MJ, Marks GF, Tawa CB, Zoghbi WA, Young JB, Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am J Cardiol 1994 73 881 886
30. Ahmad T, Pencina MJ, Schulte PJ, O'Brien E, Whellan DJ, Piña IL, Kitzman DW, Lee KL, O'Connor CM, Felker GM, Clinical implications of chronic heart failure phenotypes defined by cluster analysis. J Am Coll Cardiol 2014 64 1765 1774. doi: 10.1016/j.jacc.2014.07.979
31. Hasenfuss G, Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res 1998 37 279 289
32. European Society of Cardiology. Largest study to date show no benefit to gene transfer therapy in heart failure. (press release). September 1, 2015. http://www.escardio.org/The-ESC/Press-Office/Press-releases/Last-5-years/largest-study-To-date-shows-no-benefit-To-gene-Transfer-Therapy-in-heart-failure Accessed December 28, 2015
33. Shah MR, Stevenson LW, Searching for evidence: refractory questions in advanced heart failure. J Card Fail 2004 10 210 218
34. Gupta R, Tang WH, Young JB, Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic. Am Heart J 2004 147 79 83
35. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE, Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-Analytic approach. J Am Coll Cardiol 2010 56 392 406. doi: 10.1016/j.jacc.2010.05.011
36. Braunwald E, The management of heart failure: the past, the present, and the future. Circ Heart Fail 2008 1 58 62. doi: 10.1161/CIRCHEARTFAILURE.107.752162
37. Martino TA, Sole MJ, Molecular time: an often overlooked dimension to cardiovascular disease. Circ Res 2009 105 1047 1061. doi: 10.1161/CIRCRESAHA.109.206201
38. Costa MA, Mazzaferri EL Jr, Sievert H, Abraham WT, Percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure: three-year outcomes of the PARACHUTE first-in-human study. Circ Heart Fail 2014 7 752 758. doi: 10.1161/CIRCHEARTFAILURE.114.001127
39. Wechsler AS, Sadowski J, Kapelak B, Bartus K, Kalinauskas G, Rucinskas K, Samalavicius R, Annest L, Durability of epicardial ventricular restoration without ventriculotomy. Eur J Cardiothorac Surg 2013 44 e189 192. discussion e192. doi: 10.1093/ejcts/ezt292
40. A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure (AUGMENT-HF), https://clinicaltrials.gov/ct2/show/NCT01311791 Accessed January 9, 2016
41. McCarthy JF, McCarthy PM, Starling RC, Smedira NG, Scalia GM, Wong J, Kasirajan V, Goormastic M, Young JB, Partial left ventriculectomy and mitral valve repair for end-stage congestive heart failure. Eur J Cardiothorac Surg 1998 13 337 343
42. Mann DL, Acker MA, Jessup M, Sabbah HN, Starling RC, Kubo SH, Acorn Trial Principal Investigators and Study Coordinators Clinical evaluation of the CorCap Cardiac Support Device in patients with dilated cardiomyopathy. Ann Thorac Surg 2007 84 1226 1235. doi: 10.1016/j.athoracsur.2007.03.095
43. Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL, STICH Hypothesis 2 Investigators Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009 360 1705 1717. doi: 10.1056/NEJMoa0900559
44. Burkhoff D., Weschsler AS, Surgical ventricular remodeling: a balancing act on systolic and diastolic properties. J Thorac Cardiovasc Surg 2006 132 459 463
45. Balwin JT, Watson JT, Kormos R, Miller LW, Historical aspects of mechanical circulatory support. In: Mechanical Circulatory Support, a Companion to Braunwald's Heart Disease 2012 Philadelphia PA Saunders 1 10
46. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Miller MA, Timothy Baldwin J, Young JB, Sixth INTERMACS annual report: a 10,000-patient database. J Heart Lung Transplant 2014 33 555 64
47. Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, Naftel DC, Ulisney K, Desvigne-Nickens P, Kirklin JK, INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009 28 535 541. doi: 10.1016/j.healun.2009.02.015
48. Grady KL, Naftel D, Stevenson L, Dew MA, Weidner G, Pagani FD, Kirklin JK, Myers S, Baldwin T, Young J, Overall quality of life improves to similar levels after mechanical circulatory support regardless of severity of heart failure before implantation. J Heart Lung Transplant 2014 33 412 421. doi: 10.1016/j.healun.2013.10.017
49. Ryan TJ, Graham TP, Annas GJ, DeMaria AN, Fost NC, Fuster V, Harvey JC, Levinsky NG, McCullough LB, Rettig RA, Schwartz WJ, Sundwall DN, Talner NS, Wigle ED, Willman VL, Task Force III: Perspectives on the allocation of limited resources in cardiovascular medicine. J Am Coll Cardiol 1990 16 17 23
50. Ambardekar AV, Buttrick PM, Reverse remodeling with left ventricular assist devices: a review of clinical, cellular, and molecular effects. Circ Heart Fail 2011 4 224 233. doi: 10.1161/CIRCHEARTFAILURE.110.959684
51. Ascheim DD, Gelijns AC, Goldstein D, Moye LA, Smedira N, Lee S, Klodell CT, Szady A, Parides MK, Jeffries NO, Skerrett D, Taylor DA, Rame JE, Milano C, Rogers JG, Lynch J, Dewey T, Eichhorn E, Sun B, Feldman D, Simari R, O'Gara PT, Taddei-Peters WC, Miller MA, Naka Y, Bagiella E, Rose EA, Woo YJ, Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation 2014 129 2287 2296. doi: 10.1161/CIRCULATIONAHA.113.007412
52. Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, Dobbels F, Goldfarb SB, Levvey BJ, Meiser B, Yusen RD, Stehlik J, International Society of Heart and Lung Transplantation The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report-2014; focus theme: retransplantation. J Heart Lung Transplant 2014 33 996 1008. doi: 10.1016/j.healun.2014.08.003
53. Stevenson LW, Crisis awaiting heart transplantation: sinking the lifeboat. JAMA Intern Med 2015 175 1406 1409. doi: 10.1001/jamainternmed.2015.2203
54. Stehlik J, Stevenson LW, Edwards LB, Crespo-Leiro MG, Delgado JF, Dorent R, Frigerio M, Macdonald P, MacGowan GA, Nanni Costa A, Rogers JG, Shah AS, Taylor R, Venkateswaran RV, Mehra MR, Organ allocation around the world: insights from the ISHLT International Registry for Heart and Lung Transplantation. J Heart Lung Transplant 2014 33 975 984. doi: 10.1016/j.healun.2014.08.001
55. Teuteberg JJ, Stewart GC, Jessup M, Kormos RL, Sun B, Frazier OH, Naftel DC, Stevenson LW, Implant strategies change over time and impact outcomes: insights from the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). JACC Heart Fail 2013 1 369 378. doi: 10.1016/j.jchf.2013.05.006
56. Gaasch WH, Battle WE, Oboler AA, Banas JS Jr, Levine HJ, Left ventricular stress and compliance in man. With special reference to normalized ventricular function curves. Circulation 1972 45 746 762
57. Little WC, Borlaug BA, Exercise intolerance in heart failure with preserved ejection fraction: what does the heart have to do with it? Circ Heart Fail 2015 8 233 235. doi: 10.1161/CIRCHEARTFAILURE.114.001966
58. Zile MR, Baicu CF, Gaasch WH, Diastolic heart failure-Abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004 350 1953 1959. doi: 10.1056/NEJMoa032566
59. Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, Kass DA, Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006 114 2138 2147. doi: 10.1161/CIRCULATIONAHA.106.632745
60. Dhakal BP, Malhotra R, Murphy RM, Pappagianopoulos PP, Baggish AL, Weiner RB, Houstis NE, Eisman AS, Hough SS, Lewis GD, Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction. Circ Heart Fail 2015 8 286 294. doi: 10.1161/CIRCHEARTFAILURE.114.001825
61. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM, Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010 3 588 595. doi: 10.1161/CIRCHEARTFAILURE.109.930701
62. Paulus WJ, Tschöpe C, A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013 62 263 271. doi: 10.1016/j.jacc.2013.02.092
63. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM, Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015 131 550 559. doi: 10.1161/CIRCULATIONAHA.114.009625
64. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC, Deo RC, Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 2015 131 269 279. doi: 10.1161/CIRCULATIONAHA.114.010637
65. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, ESC Committee for Practice Guidelines ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012 33 1787 1847. doi: 10.1093/eurheartj/ehs104
66. Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE, I-PRESERVE Investigators Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011 124 2491 2501. doi: 10.1161/CIRCULATIONAHA.110.011031
67. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O'Meara E, Desai AS, Heitner JF, Li G, Fang J, Rouleau J, Zile MR, Markov V, Ryabov V, Reis G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD, Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail 2014 7 740 751. doi: 10.1161/CIRCHEARTFAILURE.114.001583
68. Santos M, Rivero J, McCullough SD, West E, Opotowsky AR, Waxman AB, Systrom DM, Shah AM, E/e' ratio in patients with unexplained dyspnea: lack of accuracy in estimating left ventricular filling pressure. Circ Heart Fail 2015 8 749 756. doi: 10.1161/CIRCHEARTFAILURE.115.002161
69. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987 316 1429 35
70. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B, Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015 131 34 42. doi: 10.1161/CIRCULATIONAHA.114.013255
71. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). https://clinicaltrials.gov/ct2/show/NCT01920711 Accessed January 12, 2016
72. Mascherbauer J, Marzluf BA, Tufaro C, Pfaffenberger S, Graf A, Wexberg P, Panzenböck A, Jakowitsch J, Bangert C, Laimer D, Schreiber C, Karakus G, Hülsmann M, Pacher R, Lang IM, Maurer G, Bonderman D, Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Imaging 2013 6 1056 1065. doi: 10.1161/CIRCIMAGING.113.000633
73. Kitzman DW, Hundley WG, Brubaker PH, Morgan TM, Moore JB, Stewart KP, Little WC, A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail 2010 3 477 485. doi: 10.1161/CIRCHEARTFAILURE.109.898916
74. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, RELAX Trial Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013 309 1268 1277. doi: 10.1001/jama.2013.2024
75. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B, Aldo-DHF Investigators Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013 309 781 791. doi: 10.1001/jama.2013.905
76. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E, NHLBI Heart Failure Clinical Research Network Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2015 373 2314 2324. doi: 10.1056/NEJMoa1510774
77. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC, Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail 2010 3 659 667. doi: 10.1161/CIRCHEARTFAILURE.110.958785
78. Interleukin-1 Blockade in HF With Preserved EF (D-HART2). https://www.clinicaltrials.gov/ct2/show/NCT02173548?term=heart+failure+preserved+ejection+fraction&rank=43 Accessed January 9, 2016
79. CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD). https://clinicaltrials.gov/ct2/show/NCT02499601 Accessed January 9, 2016
80. Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure (RAPID-HF). https://www.clinicaltrials.gov/ct2/show/NCT02145351?term=heart+failure+preserved+ejection+fraction&rank=28 Accessed January 9, 2016
81. REDUCE LAP-HF TRIAL (REDUCE LAP-HF). https://clinicaltrials.gov/ct2/show/NCT01913613 Accessed January 9, 2016
82. Finkelstein DM, Schoenfeld DA, Combining mortality and longitudinal measures in clinical trials. Stat Med 1999 18 1341 1354
83. Pocock SJ, Ariti CA, Collier TJ, Wang D, The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 2012 33 176 182. doi: 10.1093/eurheartj/ehr352
84. Felker GM, Maisel AS, A global rank end point for clinical trials in acute heart failure. Circ Heart Fail 2010 3 643 646. doi: 10.1161/CIRCHEARTFAILURE.109.926030
85. Fallick C, Sobotka PA, Dunlap ME, Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail 2011 4 669 675. doi: 10.1161/CIRCHEARTFAILURE.111.961789
86. Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure (TRUE-AHF). https://clinicaltrials.gov/ct2/show/NCT01661634 Accessed January 9, 2016
87. Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF (RELAX-AHF-2). https://clinicaltrials.gov/ct2/show/NCT01870778?term=serelaxin&rank=9 Accessed January 9, 2016
88. Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B, SOCRATES-REDUCED Investigators and Coordinators Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED Randomized Trial. JAMA 2015 314 2251 2262. doi: 10.1001/jama.2015.15734
89. Kheirbek RE, Fletcher RD, Bakitas MA, Fonarow GC, Parvataneni S, Bearden D, Bailey FA, Morgan CJ, Singh S, Blackman MR, Zile MR, Patel K, Ahmed MB, Tucker RO, Brown CJ, Love TE, Aronow WS, Roseman JM, Rich MW, Allman RM, Ahmed A, Discharge hospice referral and lower 30-day all-cause readmission in Medicare beneficiaries hospitalized for heart failure. Circ Heart Fail 2015 8 733 740. doi: 10.1161/CIRCHEARTFAILURE.115.002153
90. Konstam MA, Upshaw J, Sisyphus and 30-day heart failure readmissions: futility in predicting a flawed outcome metric. JACC Heart Fail 2016 4 21 23. doi: 10.1016/j.jchf.2015.10.002
91. HCMR-Novel Markers of Prognosis in Hypertrophic Cardiomyopathy (HCMR). https://clinicaltrials.gov/ct2/show/NCT01915615 Accessed January 18, 2016
92. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS, Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014 130 484 495. doi: 10.1161/CIRCULATIONAHA.113.007094
93. Ho CY, Day SM, Ashley EA, Michels M, da Cost Pereria A, Fox J, Caleshu CA, Cirino AL, Colan SD, Wrolstad D, Green E, Olivotto I, for the SHaRe Investigators. Examining prevailing genotype-phenotype correlations in hypertrophic cardiomyopathy: findings from the Sarcomeric Human Cardiomyopathy Registry. November 9, 2015. https://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm-479148.pdf Accessed January 18, 2016
94. Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM). https://clinicaltrials.gov/ct2/show/NCT02291237?term=hypertrophic+cardiomyopathy&rank=7 Accessed January 18, 2016
95. Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461. https://clinicaltrials.gov/ct2/show/NCT02329184?term=MYK-461&rank=2 Accessed January 18, 2016
96. Udelson JE, Developing imaging biomarkers for myocardial involvement in amyloidosis: challenge and opportunity. JACC Cardiovasc Imaging 2015 8 60 62. doi: 10.1016/j.jcmg.2014.10.006
97. Ruberg FL, Berk JL, Transthyretin (TTR) cardiac amyloidosis. Circulation 2012 126 1286 1300. doi: 10.1161/CIRCULATIONAHA.111.078915
98. ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC). https://clinicaltrials.gov/ct2/show/NCT02319005?term=cardiac+amyloidosis&rank=20 Accessed January 18, 2016
99. Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy (ATTR-ACT). https://clinicaltrials.gov/ct2/show/NCT01994889?term=tafamidis&rank=5 Accessed January 18, 2016
100. The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of-Wild-Type TTR Involving the Heart. https://clinicaltrials.gov/ct2/show/NCT02627820?term=GSK+cardiac+amyloidosis&rank=1 Accessed January 18, 2016
101. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ, Detection of myocardial damage in patients with sarcoidosis. Circulation 2009 120 1969 1977. doi: 10.1161/CIRCULATIONAHA.109.851352
102. Gerber Y, Weston SA, Enriquez-Sarano M, Berardi C, Chamberlain AM, Manemann SM, Jiang R, Dunlay SM, Roger VL, Mortality associated with heart failure after myocardial infarction: a contemporary community perspective. Circ Heart Fail 2016 9 e002460. doi: 10.1161/CIRCHEARTFAILURE.115.002460
103. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM, Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015 131 1981 1988. doi: 10.1161/CIRCULATIONAHA.114.013777
104. Groarke JD, Nohria A, Anthracycline cardiotoxicity: a new paradigm for an old classic. Circulation 2015 131 1946 1949. doi: 10.1161/CIRCULATIONAHA.115.016704
105. Lala A, McNulty SE, Mentz RJ, Dunlay SM, Vader JM, AbouEzzeddine OF, DeVore AD, Khazanie P, Redfield MM, Goldsmith SR, Bart BA, Anstrom KJ, Felker GM, Hernandez AF, Stevenson LW, Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circ Heart Fail 2015 8 741 748. doi: 10.1161/CIRCHEARTFAILURE.114.001957
106. Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ, Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001 38 421 428
107. Krahnke JS, Abraham WT, Adamson PB, Bourge RC, Bauman J, Ginn G, Martinez FJ, Criner GJ, Champion Trial Study Group Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device. J Card Fail 2015 21 240 249. doi: 10.1016/j.cardfail.2014.12.008
108. Stevenson LW, Heart failure with better ejection fraction: a modern diagnosis. Circulation 2014 129 2364 2367. doi: 10.1161/CIRCULATIONAHA.114.010194
109. Punnoose LR, Givertz MM, Lewis EF, Pratibhu P, Stevenson LW, Desai AS, Heart failure with recovered ejection fraction: a distinct clinical entity. J Card Fail 2011 17 527 532. doi: 10.1016/j.cardfail.2011.03.005
110. Basuray A, French B, Ky B, Vorovich E, Olt C, Sweitzer NK, Cappola TP, Fang JC, Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation 2014 129 2380 2387. doi: 10.1161/CIRCULATIONAHA.113.006855
111. Leduc O, Crasset V, Leleu C, Baptiste N, Koziel A, Delahaie C, Pastouret F, Wilputte F, Leduc A, Impact of manual lymphatic drainage on hemodynamic parameters in patients with heart failure and lower limb edema. Lymphology 2011 44 13 20
112. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH, Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009 53 589 596. doi: 10.1016/j.jacc.2008.05.068
113. Testani JM, Brisco MA, Chen J, McCauley BD, Parikh CR, Tang WH, Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J Am Coll Cardiol 2013 62 516 524. doi: 10.1016/j.jacc.2013.05.027
114. Packer M, Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation 1985 72 681 685
115. Kheirbek RE, Fletcher RD, Bakitas MA, Fonarow GC, Parvtaneni S, Bearden D, Discharge hospice referral and lower 30-day all-cause readmission in Medicare beneficiaries hospitalized for heart failure. Circ Heart Fail 2015 8 733 740
116. Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, Cook NR, Felker GM, Francis GS, Hauptman PJ, Havranek EP, Krumholz HM, Mancini D, Riegel B, Spertus JA, American Heart Association; Council on Quality of Care and Outcomes Research; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation 2012 125 1928 1952. doi: 10.1161/CIR.0b013e31824f2173
117. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992 327 685 91
118. Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, Greenberg B, Klibaner MI, Kukin ML, Sugg JE, REVERT Study Group Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007 116 49 56. doi: 10.1161/CIRCULATIONAHA.106.666016
119. Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Bermingham M, Patle A, Badabhagni MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K, Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013 310 66 74. doi: 10.1001/jama.2013.7588
120. Wu JR, Moser DK, DeWalt DA, Rayens MK, Dracup K, Health literacy mediates the relationship between age and health outcomes in patients with heart failure. Circ Heart Fail 2016 9 e002250. doi: 10.1161/CIRCHEARTFAILURE.115.002250
121. Udelson JE, T.M.I. (Too much information)? Circulation 2011 124 1697 1699. doi: 10.1161/CIRCULATIONAHA.111.067819